Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA adverse event reporting system database (FAERS)
Description
CONCLUSIONS: Our study identified signals for DVT with baricitinib, tofacitinib and upadacitinib. Further research using well-designed epidemiological data is needed to validate these results.
